Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (182)
  2. Journal Article (79)
  3. Research Letter (18)
  4. Review (18)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (310)
  2. Hematologic Malignancies, Division of (310)
  3. Center for Hematologic Malignancies (168)
  4. Lymphoma (164)
  5. Hematology-Oncology Fellows (141)
  6. Survivorship Research (118)

More Groups

People
  1. Maria Palomba (112)
  2. Andrew Zelenetz (76)
  3. Anita Kumar (66)
  4. Lorenzo Falchi (66)
  5. Gunjan Shah (63)
  6. Miguel-Angel Perales (60)

More People

Years
  1. 2025 (26)
  2. 2024 (68)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (127)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (18)
  4. Blood Advances (16)
  5. Haematologica (15)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (21)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (15)
  6. Nature Publishing Group (14)

More Publishers

Results (310)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comparison of overall survival with brexucabtagene autoleucel (brexu-cel) CAR T-cell therapy (ZUMA-2) and standard of care (SCHOLAR-2) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) previously treated with a covalent bruton tyrosine kinase inhibitor (BTKi)
    Meeting Abstract

    Hess, G.; Dreyling, M.; Oberic, L.; Gine, E.; Zinzani, P. L.; Linton, K. M.; Vilmar, A.; Jerkeman, M.; Chen, J. M. H.; Ohler, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Final results of a phase Ib/II randomized study and single-arm extension (Ext) study
    Meeting Abstract

    Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A. K.; Özcan, M.; Safar, V.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Precision targeting of MYD88 mutant DLBCL using the novel combination of irakimids and BCL2 inhibition
    Meeting Abstract

    Grilo, A. M.; Klaus, C.; McDonald, A.; Gollob, J.; Weiss, M.; O'Connor, O. A.; Salles, G.; Chaudhuri, J.; Lue, J. K.
    Blood (2022)

    Fulltext@MSK | Save
  • Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) in terms of second line (2L) treatment: An ad hoc analysis from the POLARIX study
    Meeting Abstract

    Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; Ho, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • L-Mind: A safety and efficacy analysis of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving treatment for at least 2 years
    Meeting Abstract

    Duell, J.; Jurczak, W.; Liberati, A. M.; Halka, J.; Pena Carbó, E.; Abrisqueta Costa, P.; Maddocks, K. J.; Dreyling, M.; Rosenwald, A.; Bakuli, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL) treated with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in the phase III POLARIX study
    Meeting Abstract

    Friedberg, J. W.; Thompson, C. A.; Trněný, M.; Morschhauser, F.; Salles, G.; Reagan, P. M.; Hertzberg, M.; Smolewski, P.; Zhang, H.; Thieblemont, C.; more...
    Blood (2022)

    Fulltext@MSK | Save